Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Li J, 2022 NCT04892459

CanSino (Convidecia) (n=147) vs. CoronaVac (SinoVac) (n=152)

randomized controlled trial   risk of bias NA

Studied treatment

Ad-5 based vaccine (D2 or D3)

Control treatment

inactivated Coronavac vaccine (D2 or D3)

Patients

COVID-19 prophylaxis (excluding children)

Method

single-blind

1 center, China

Remark

CanSino phase 2 (Zhu), 2020 NCT04341389

CanSino (Convidecia) (n=382) vs. placebo (n=126)

randomized controlled trial   risk of bias NA

Studied treatment

CanSino
1×10¹¹ or 5×10¹⁰ viral particles per mL - 1 injection

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double-blind

single centre in Wuhan, China

The secondary safety outcomes included the occurrence of adverse events from days 0 to 28 after vaccination, and serious adverse events reported up to 6 months

Remark

Fengcai, 2021 NCT04566770

CanSino (Convidecia) (n=320) vs. placebo (n=110)

randomized controlled trial   risk of bias NA

Studied treatment

low-dose vaccine, middle-dose, 2 doses

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double blind

1 center, China

Remark